Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure

Current Cardiology Reports

Volumn 2, Issue 3, 2000, Pages 233-243

  Lehtonen, Lasse ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; VASODILATOR AGENT;

ANIMAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART CONTRACTION; HEMODYNAMICS; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYDRAZONES; MYOCARDIAL CONTRACTION; PYRIDAZINES; VASODILATOR AGENTS;

EID: 0034185033     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0074-6     Document Type: Article

References (75)

1. Packer M, Carver JR, Rodeheffer RJ, et al. : Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991, 325:1468-1475.
2. Cohn JN, Goldstein SO, Greenberg BH, et al. : A dosedependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998, 339:1810-1816.
3. Leier CV, Binkley PH: Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998, 41:207-224.
4. Du Toit EF, Muller CA, McCarthy J, Opie LH: Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999, 290:505-514.
5. Ver Donck L: Calcium-sensitizing drugs: positive inotropy by enhanced sensitivity of the contractile apparatus to calcium. Cardiovasc Drug Rev 1996, 14:185-212.
6. Feldman AM: Classification of positive inotropic agent. J Am Coll Cardiol 1993, 22:1223-1227.
7. Haikala H, Lindén I-B: Mechanisms of action of calciumsensitizing drugs. J Cardiovasc Pharmacol 1995, 1. (suppl 1):S10-S19.
8. Pollesello P, Ovaska M, Kaivola J, et al. : Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. J Biol Chem 1994, 269:28584-28590.
9. Haikala H, Kaivola J, Nissinen E, et al. : Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995, 27:1859-1866.
10. Haikala H, Nissinen E, Etemadzadeh E, et al. : Troponin Cmediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995, 25:794-801.
11. Kleerekoper Q, Putkey JA: Drug binding to cardiac troponin C. J Biol Chem 1999, 274:23932-23939.
12. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997, 333:249-259.
13. Végh A, Papp JG, Udvary E, Kaszala K: Hemodynamic effects of calcium-sensitizing agents. J Cardiovasc Pharmacol 1995, 26(suppl 1):S20-S31.
14. Rump AF, Acar D, Rosen R, Klaus W: Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994, 74:24424-24428.
15. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis NH: The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exptl Ther 1997, 283:375-383.
16. Kersten JR, Montgomery MW, Pagel PS, Warltier DC: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000, 90:5-11.
17. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al. : Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998, 31:741-749.
18. Nichlas JM, Monsur JC, Bleske BE: Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999, 83(suppl 12B):12-15.
19. Boknik P, Neumann J, Kaspareit G, et al. : Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exptl Ther 1997, 280:277-283.
20. Sato S, Talukder MA, Sugawara H, et al. : Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998, 30:1115-1128.
21. Edes I, Kiss E, Kitada Y, et al. : Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995, 77:107-113.
22. Zimmermann N, Boknik P, Gams E, et al. : Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Eur J Cardiothorac Surg 1998, 14:70-75.
23. Hasenfuss G, Pieske B, Castell M, et al. : Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998, 98:2141-2147.
24. Haikala H, Kaheinen P, Levijoki J, Linden IB: The role of cAMP-and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997, 34:536-546.
25. Pagel PS, Haikala H, Pentikäinen P, et al. : Pharmacology of levosimendan: a new myofilament calcium sensitizer. Cardiovasc Drug Rev 1996, 14:286-316.
26. Pagel PS, Harkin CP, Hettrick DA, Warltier DC: Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994, 81:974-987.
27. Udvary E, Papp JG, Vegh A: Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Br J Pharmacol 1995, 114:656-661.
28. Mester L, Udvary E, Papp JG: The long term haemodynamic effects of levosimendan in conscious trained dogs [abstract]. J Mol Cell Cardiol 1994, 26:LXXXV.
29. Pagel PS, McGough MF, Hettrick DA, et al. : Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997, 29:563-573.
30. Todaka K, Wang J, Yi GH, et al. : Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exptl Ther 1996, 279:120-127.
31. Pagel PS, Hettrick DA, Warltier DC: Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 1996, 91:296-307.
32. Sandell EP, Häyhä M, Antila S, et al. : Pharmacokinetics of levosimendan in healthy volunteers and in patients with congestive heart failure. J Cardiovasc Pharmacol 1995, 26(suppl 1):S57-S62.
33. Pentikäinen P, Antila S, Kivikko M, et al. : Pharmacokinetics of levosimendan in patients with severe congestive heart failure. Abstract. 3rd Annual Scientific Meeting of the Heart Failure Society of America, San Francisco, CA, Sept. 22-25, 1999. J Cardiac Failure 1999, 5:48.
34. Lilleberg J, Sundberg S, Hayha M, et al. : Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994, 47:267-274.
35. Kaila T, Grönroos P, Scheinin H, et al. : Effects of intravenous levosimendan on cardiovascular autonomic regulation in healthy volunteers. Thérapie 1994, 50(suppl 1):abstract 304.
36. Antila S, Honkanen T, Lehtonen L, Neuvonen PJ: The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther 1998, 36:446-449.
37. Antila S, Huuskonen H, Nevalainen T, et al. : Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 1999, 9:85-91.
38. Kristof E, Szigeti G, Papp Z, et al. : Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann N Y Acad Sci 1998, 853:316-319.
39. Sundberg S, Antila S, Scheinin H, et al. : Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 1998, 36:629-635.
40. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L: Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995, 75:1061-1066.
41. Lilleberg J, Sundberg S, Nieminen M: Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995, 26(suppl. 1):S63-S69.
42. Ukkonen H, Saraste M, Akkila J, et al. : Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997, 61:596-607.
43. Ukkonen HJ, Saraste M, Akkila JH, et al. : Energetical effects of levosimendan in congestive heart failure as assessed with positron emission tomography. 69th Scientific Sessions of American Heart Association, New Orleans, LA, November 10-1. 1996. Circulation 1996, 94 (suppl I):I-556.
44. Ukkonen HJ, Saraste M, Akkila JH, et al. : Effects of levosimendan, a calcium sensitizer, on right and left ventricular energetics in heart failure. a PET study. XIXth Congress of the European Society of Cardiology, Stockholm, Sweden, August 24-28, 1997. Eur Heart J 1997, 18(suppl):573.
45. Weterings CJ, Prinzen FW, Reneman RS, de Lange S: The effect of the calcium sensitizer levosimendan on normal and stunned left ventricular myocardium [abstract]. Br J Anesth 1996, 76(suppl 1):4.
46. Jamali IN, Kersten JR, Pagel PS, et al. : Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997, 85:23-29.
47. Lilleberg J, Nieminen MS, Akkila J, et al. : Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998, 19:660-668.
48. Nijhawan N, Nicolosi AC, Montgomery MW, et al. : Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999, 34:219-228.
49. Luotolahti M, Lammintausta O, Ukkonen H, et al. : Levosimendan, a calcium sensitizer and potassium channel opener, is safe and improves left ventricular function in acute myocardial infarction. 71st Scientific Sessions of the American Heart association, Dallas, TX, November 8-11, 1998. Circulation 1998, 98(suppl I):535.
50. Sonntag S, Wellnhofer E, Opitz C, et al. : Effects of the calcium sensitizer levosimendan on stunned myocardium after percutaneous transluminal coronary angioplasty. Abstract. 72nd Scientific sessions of the American Heart Association, Atlanta, GA, Nov 7-10, 1999. Circulation 1999, 100(suppl):I-79.
51. Nyquist O, Hasenfuss G, Kleber F, et al. : Hemodynamic effects of continuous infusion of levosimendan in patients with congestive heart failure [abstract]. XIXth Congress of the European Society of Cardiology, Stockholm, Sweden, August 24-28, 1997. Eur Heart J 1997, 18(suppl):643.
52. Slawsky MT, Colucci W, Leier CV, et al. : Hemodynamic effects of levosimendan, a novel calcium-sensitizer with vasodilating properties, in patients with severe heart failure: a double-blind, placebo-controlled trial. XIII World Congress of Cardiology, Rio de Janeiro, Brazil, 26-30 April 1998. JACC 1998, 31(Suppl C):265C.
53. Nieminen MS, Hasenfuss G, Kleber F, et al. : Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with heart failure. XIII World Congress of Cardiology, Rio de Janeiro, Brazil, 26-30 April 1998. JACC 1998, 31 (Suppl C):86C.
54. Nieminen MS, Moiseyev VS, Andrejevs N, et al. : Randomized study on safety and effectiveness of levoismendan in patients with left ventricular failure after an acute myocardia infarct. Abstract. 72nd Scientific sessions of the American Heart Association, Atlanta, GA, Nov 7-10, 1999. Circulation 1999 (suppl):I-646.
55. Follath F, Hinkka S, Jäger D, et al. : Dose-ranging and safety with intravenous levoismendan in low-output heart failure: Experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol 1999, 83 (suppl 12B):21-25.
56. Bates ER, Topol EJ: Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991, 18:1077-1084.
57. Follath F, Cleland JFG, Just H, et al. : Efficacy and safety of intravenous levosimendan in severe low-output failure. Abstract. 72nd Scientific sessions of the American Heart Association, Atlanta, GA, Nov 7-10, 1999. Circulation 1999, 1. (suppl):I-646.
58. Harjola VP, Peuhkurinen K, Nieminen MS, et al. : Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol 1999, 83(suppl 12B):4-8.
59. Hosenpud JD, and the oral levosimendan study group: Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 1999, 83(suppl 12B):9-11.
60. Lehtonen L, Mills-Owens P, Akkila J: Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol 1995, 26(suppl 1):S70-S76.
61. Varro A, Papp JG: Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed. J Cardiovasc Pharmacol 1995, 26(suppl 1):S32-S34.
62. Toivonen L, Viitasalo M, Lehtonen L, et al. : Electrophysiologic effects of a calcium sensitizer inotrope levosimendan in patients with normal cardiac function [abstract]. American College of Cardiology, 46th Annual Scientific Session, Anaheim, CA, March 16-19, 1997. JACC 1997, 29(suppl A):41A-42A.
63. Singh BN, Lilleberg J, Sandell EP, et al. : Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase IIII clinical studies in cardiac failure. Am J Cardiol 1999, 83(suppl 12B):9-11.
64. Antila S, Eha J, Heinpalu M, et al. : Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996, 49:451-458.
65. Lehtonen L, Antila S, Eha J, et al. : No pharmacodynamic interactions between a new calcium sensitizing agent levosimendan and a calcium antagonist drug felodipine. Eur J Clin Pharmacol 1997, 52(suppl):A136.
66. Antila S, Järvinen A, Honkanen T, et al. : A new calcium sensitizing agent levosimendan has no pharmacokinetic or pharmacodynamic interactions with warfarin [abstract]. Eur J Clin Pharmacol 1997, 52(suppl):A128.
67. Sundberg S, Lehtonen L: Hemodynamic interactions between levosimendan, a new calcium sensitizer, and isosorbide-5-mononitrate in healthy subjects. 2nd Congress of European Association for Clinical Pharmacology and Therapeutics, Berlin, Germany, September 17-20, 1997. Eur J Clin Pharmacol 1997, 52 (suppl):A381.
68. Lubsen J, Just H, Hjalmarsson AC, et al. : Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996, 76:223-231.
69. United States Food and Drug Administration Center For Drug Evaluation and Research Division of Cardio-Renal Drug Products. Cardiovascular and Renal Drugs Advisory Committee 87th Meeting, Friday, January 29, 1999. Bethesda, MD. http://www. fda. gov/ohrms/dockets/ac/99/transcpt/3490t2. rtf
70. Feldman AM, Bristow MR, Parmley WW, et al. : Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993, 329:149-155.
71. Parmley W: Surviving heart failure: Robert L. Frye Lecture. Mayo Clin Proc 2000, 75:111-118.
72. Francis GS, Anwar FB, Bank JA, et al. : Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail 1999, 5:308-315.
73. Cuffe MS, Califf RM, Adams KF, et al. : Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J 2000, 139:15-22.
74. Pagel PS, Harkin CP, Hettrick DA, Warltier DC: Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs. J Pharmacol Exptl Ther 1995, 275:127-135.
75. McGough MF, Pagel PS, Lowe D, et al. : Levosimendan potentiates the inotropic actions of dopamine in conscious dogs. J Cardiovasc Pharmacol 1996, 28:36-47.